Embolic Protection Devices during percutaneous cardiac procedures (PCI and TAVI)

Number of report

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for use of Embolic Protection Devices during percutaneous cardiac procedures. 

The following clinical situations are considered: 

  • Use of Embolic Protection Device during percutaneous transluminal coronary angioplasty with insertion of single bare metal stent
  • Use of Embolic Protection Device during percutaneous transluminal transcatheter aortic valve replacement

The only reimbursement within public / statutory health insurance systems is considered.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of Embolic Protection Devices for percutaneous cardiac procedures (PCI and TAVI):

  • Allium Medical (WIRION EPD)
  • Boston Scientific (FilterWire EZ)
  • Claret Medical (Sentinel)
  • Contego Medical
  • Cordis (ANGIOGUARD)
  • Innovative Cardiovascular Solutions (Emblock)
  • Keystone Heart Ltd (TriGuard)
  • Transverse Medical (POINT-GUARD)

Table of content is not available at the moment. Report is still ongoing.


Dec 2020

In November 2020, the National Institute for Health and Care Excellence (NICE) published one new interventional procedure guidance (for swallowable gastric balloon capsule for weight loss), five Medtech innovation briefings (for QuickChange Incontinence Wrap for urinary incontinence in men, Magseed for locating breast cancer lesions, Dexcom G6 for continuous glucose monitoring, and others). Also, one clinical guidance (for acute coronary syndromes) was updated.

Read more


Nov 2020

On October 30, 2020, the Swiss Federal Statistics Office (UFS) published the 2021 version of the procedure code (CHOP) nomenclature in French and Italian. The version in the German language was published in July 2020. The most important changes regard cardiovascular and peripheral vascular interventions.

Read more


Oct 2020

In October 2020, a completed mini-method assessment for the coronary sinus reducer stent (Neovasc) implantation in refractory angina pectoris treatment was published within the New Methods framework. The Oslo University Hospital carried out the evaluation. The technology was recommended for routine use in hospitals.

Read more


Oct 2020

On September 30, 2020, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) published the position that transcatheter aortic valve implantation (TAVI) in patients with aortic stenosis and a high risk of surgery is eligible for reimbursement under basic health insurance package.

Read more


Oct 2020

On August 6, 2020, the Ministry of Solidarity and Health published an Order (of August 4, 2020) listing the rotational atherectomy systems ROTAPRO and ROTALINK PLUS of the company Boston Scientific under Title V of the list of reimbursable products and services provided for in Article L. 165-1 of the Social Security Code (LPPR List).

Read more
(we accept only company emails)